Allergan Plc (AGN)
Allergan Aesthetics and University Lab Partners Announce the Golden Ticket Pitch Competition to Accelerate Aesthetics Start-Ups
Irvine, California--(Newsfile Corp. - April 11, 2024) - University Lab Partners (ULP) is thrilled to announce the return of the...
AbbVie cites tailwinds to Botox sales from weight loss drugs
AbbVie's (ABBV) wrinkle therapy Botox-led aesthetics franchise may benefit from the increasing demand for obesity drugs in the long-term. Find out the reasons.
AbbVie sees maintaining Botox position in aesthetics: report (NYSE:ABBV)
Despite increasing competition, AbbVie reportedly expects Botox to maintain its leading market share position in the aesthetics market. Read more here.
BioMarin could be very 'digestible' to larger cap peers in US/Europe - analyst
BioMarin's shares surge 12% after activist investor Elliott Management takes $1 billion stake; potential takeover target for larger cap peer.
AbbVie Allergan reports positive Phase 3 data for new wrinkle treatment (NYSE:ABBV)
AbbVie (ABBV) Allergan Aesthetics reports positive Phase 3 results for its new wrinkle therapy, BoNT/E, for the treatment of glabellar lines between eyebrows. Read more here.
A Comprehensive Study Exploring Obesity Treatment Market : Key Players Orexigen Therapeutics, Cousin Biotech, EnteroMedics
Get an extensive Obesity Treatment Market analysis of the dominant vendors, their latest products and services, and the competitive landscape of the industry.
AbbVie says late-stage study supports Botox for platysma prominence
Allergan Aesthetics, a unit of AbbVie (ABBV), said that top-line results from a second phase 3 trial of Botox (onabotulinumtoxin A) for a muscle disruption that impacts the face and...
Lifestyle Drugs Market to See Huge Growth by 2028 : Alkermes, AstraZeneca, Pfizer, BMS
Lifestyle Drugs Comprehensive Study by Type (Depression, Dermatology, Sexual dysfunction, Obesity), Application (Children, Adults, Senior Citizens), Form (Tablets, External Use, Injection) Players and Region - Global Market Outlook to 2027
Teva settles price-fixing claims with State of Kentucky for $1.41M (NYSE:TEVA)
Teva Pharmaceutical Industries (TEVA) has agreed to pay $1.41M to settle the State of Kentucky's price-fixing claims against the company. Read more here.
Teva settles price-fixing claims with State of Kentucky for $1.41B (TEVA)
Teva Pharmaceutical Industries (TEVA) has agreed to pay $1.41B to settle the State of Kentucky's price-fixing claims against the company. Read more here.
Walgreens to pay $500M to settle opioid litigation in New Mexico (NASDAQ:WBA)
Walgreens (WBA) has agreed to pay $500M to the State of New Mexico to settle litigation stemming from how it handled prescriptions for opioids in that state. Read more here.
Teva, Walgreens, CVS, AbbVie to pay $17.3B in national opioid settlement (NYSE:TEVA)
Teva Pharmaceutical Industries (TEVA), Walgreens Boots Alliance (WBA), CVS Health (CVS) and AbbVie's (ABBV) Allergan will pay $17.3B as part of a national opioid settlement.
UPDATE 1-AstraZeneca to stop developing Crohn's disease drug
British drugmaker AstraZeneca said on Thursday it would stop developing its drug brazikumab to treat inflammatory bowel diseases, including Crohn's disease and ulcerative colitis. The company said the discontinuation was due to a delay in the drug's development timeline, affected by global events and "the context of a competitive landscape". AstraZeneca regained the rights to brazikumab from Allergan in 2020 following U.S. drugmaker AbbVie's $63 billion tie-up with Allergan.
Lifestyle Drugs Market to Eyewitness Massive Growth : Eli Lilly, Pfizer, BMS, AstraZeneca
Stay up-to-date with Lifestyle Drugs Market research offered by AMA Research. Check how key trends and emerging drivers are shaping this industry growth.
Pfizer bond offering to fund Seagen deal among largest
Pfizer (PFE) got over $85B orders Tuesday in an investment-grade jumbo bond sale, one of the biggest in history, to fund its Seagen (SGEN) acquisition. Read more here.
Cutera new advisor Taylor Harris said to be likely CEO candidate (NASDAQ:CUTR)
Taylor Harris, who was appointed to the Cutera (CUTR) board earlier this week amid a cooperation agreement with two large shareholders, is said to be a likely candidate for the...
Meet the 100 Women Who Are Leading Finance Into the Future
Our fourth annual list highlights leaders who have taken diverse paths to positions of prominence. Here’s how they’re influencing change in corporate boardrooms, the government, the Fed, and more.
Hyperhidrosis Treatment Market Projected to Show Strong Growth: Dermira, Revance Therapeutics, Ulthera, TheraVida
Get an extensive Hyperhidrosis Treatment Market analysis of the dominant vendors, their latest products and services, and the competitive landscape of the industry.
Endo launches 1st generic of Allergan's ulcer bacterial infection drug Pylera
Endo International (ENDPQ) said its operating company Par Pharmaceutical started shipping the first generic version of Allergan's Pylera 140 mg, 125 mg and 125 mg capsules in the...
Jessie Poole Nominated As 2023 National Trainer For CoolSculpting
Beauty Health stock falls amid new short report from The Bear Cave
Beauty Health Co. (SKIN) dropped 7% amid a new short report from The Bear Cave.The Bear Cave report highlights competition that Beauty Health's HydraFacial device has with DiamondGlow,...
Top 10 things the Club is watching in the stock market Wednesday: Retail sales up, stocks dip, Airbnb soars
The Dow, the S&P 500 and the Nasdaq are set to open lower as investors digest the implications of Wednesday's stronger retail sales.
%2Fcloudfront-us-east-2.images.arcpublishing.com%2Freuters%2FXS5566MUNRKT7M2W4TN7NEAQDI.jpg)
Bausch + Lomb to name Brent Saunders as CEO - WSJ
Eye-care company Bausch + Lomb Corp is expected to name Brent Saunders, the former chief executive of Allergan, as its CEO and chairman of board, the Wall Street Journal reported on Wednesday, citing people familiar with the matter.
Tissue Engineering Market Next Big Thing : Major Giants- Allergan, Biotime, B. Braun
Stay up-to-date with Tissue Engineering Market research offered by AMA Research. Check how key trends and emerging drivers are shaping this industry growth.
Anti-aging Services Market May See a Big Move : Allergan, Beiersdorf, Cutera
Stay up-to-date with Anti-aging Services Market research offered by AMA Research. Check how key trends and emerging drivers are shaping this industry growth.
Europe Infusion Therapy Market Is Expected to Grow at a CAGR of 7.2% During the Forecast Period 2023-2030
The Europe Infusion Therapy market size was valued at US$ 11,069.73 million in 2022 and is estimated to reach US$ 19,152.54 million by 2030, growing at a CAGR of 7.2% during the forecast period (2023-2030).
Abbvie plans to lift $2 billion cap on deals - WSJ
Abbvie will lift a self-imposed $2 billion limit on acquisitions and mergers placed following a $63 billion deal for Botox maker Allergan in 2020 that shot up its debt, the company's chief executive officer told the Wall Street Journal.
Abbvie plans to lift $2 billion cap on deals - WSJ
Chief Executive Officer Richard Gonzalez said the company now has the capacity "to do more", in an interview with WSJ that was published on Monday. Abbvie is hoping to replace the loss of revenue from Humira through its newer immunology drugs Skyrizi and Rinvoqn, and has forecast sales of over $21 billion from the two products in 2027.
AbbVie's Allergan unit launches new, long-lasting Juvederm dermal filler (NYSE:ABBV)
Allergan Aesthetics, a division of AbbVie (ABBV), has launched nationwide Juvederm Volux XC, long-lasting hyaluronic acid filler for severe loss of jawline definition.